Guardant Health Inc. (NASDAQ: GH) saw its stock price surge 5.14% in pre-market trading on Friday, following the release of its better-than-expected first-quarter 2025 financial results and a positive analyst update.
The cancer diagnostics company reported revenue of $203.5 million for Q1 2025, up 21% from the same period last year and exceeding analyst estimates by 7.1%. The company's net loss narrowed to $95.2 million, with a loss per share of $0.77, which was 7.6% better than expected. These strong results demonstrate Guardant Health's continued growth and improving financial performance in the competitive healthcare sector.
Adding to the positive sentiment, Morgan Stanley raised its price target on Guardant Health to $60 from $52, maintaining an Overweight rating on the stock. This upgrade reflects growing confidence in the company's future prospects. Investors appear optimistic about Guardant Health's outlook, with revenue forecast to grow 17% per annum on average over the next three years, outpacing the 7.0% growth forecast for the US Healthcare industry.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.